Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide.
Sector: Life Sciences
CardioKine
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.
Blueprint Medicines
Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Blueprint Medicines was acquired by Sanofi in 2025.
Bikam Pharmaceuticals
Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.
Adagene
Adagene (Nasdaq: ADAG) is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
Aclaris Therapeutics
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology.
Acacia Pharma
Acacia Pharma (EURONEXT: ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia developed BARHEMSYS to marketing approval and was acquired by Eagle Pharmaceuticals in 2022.
Nihal Sinha, MB BChir
Nihal Sinha is a Partner at F-Prime based in the London office and focuses primarily on biotech and life sciences in Europe and the US.
At F-Prime, Nihal was a member of the founding team of Orchard Therapeutics and an investor in Ensoma, Curie Bio, Charm Therapeutics, Aviado Bio, and T-Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.
Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.
Ketan Patel, MD
Ketan Patel is a Managing Partner with F-Prime and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.
Dr. Patel focuses on investing in therapeutics and medical device companies and has served on the Board of Directors of ABK Biomedical, Aclaris Therapeutics (NASDAQ:ACRS), Avalyn Pharma, Avivomed, Bicara Therapeutics (NASDAQ: BCAX), Caplin Steriles, Comanche Biopharma, Enzene Biosciences, Eywa Pharma, Ivenix (acquired by Fresenius Kabi), Laurus Labs (NSE:LAURUSLABS), Laurus Bio, Medwell Ventures, Menlo Therapeutics (NASDAQ:MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio (NASDAQ:RLYB), and Vicept Therapeutics (acquired by Allergan).
Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.
Alex Pasteur, PhD
Alex Pasteur joined F-Prime in 2012 and is a Partner based in London. Alex focuses on investments in therapeutics and life sciences. Alex served as founding investor in the formation of ARTBIO, Inc., Tenpoint Therapeutics Holdings Ltd and Orchard Therapeutics PLC (acquired by Kyowa Kirin). He also serves on the boards of Nodthera, Inc., Genomics Ltd, Peptone Ltd, Shift Bioscience Ltd, Owkin, Inc. and Pulmocide Ltd. He is an observer on the board of Castor.
Alex previously served on the boards of Oviva AG, Acacia Pharma (acquired by Eagle Pharmaceuticals), Arvelle Therapeutics (acquired by Angelini Pharma) and as observer for Adaptimmune Therapeutics (NASDAQ: ADAP). Alex has worked in healthcare investing since 2001. Prior to joining F-Prime, Alex worked at MVM Life Science Partners LLP in the USA and Europe. Alex holds a M.A. in Natural Sciences from Cambridge University and a PhD in Chemistry from Cambridge University.